The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the appropriate dose regimen for future studies in adult subjects with gout, with or without tophi, and hyperuricemia refractory to SoC XOI therapy.
1 Primary · 3 Secondary · Reporting Duration: 24 weeks
80 Total Participants · 4 Treatment Groups
Primary Treatment: SAP001 second study drug group · No Placebo Group · Phase 2
Age 18 - 65 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: